PartnershipJul 9, 2026, 04:13 PM
Nurix Therapeutics Partners with Roche for Bexobrutideg; $700M Upfront
AI Summary
Nurix Therapeutics announced a global collaboration agreement with Roche for its BTK degrader bexobrutideg, with potential total payments of up to $2.3 billion, including a $700 million upfront payment. This partnership will expand bexobrutideg's development into immunology and neurology, alongside its ongoing registrational program in CLL. The company reported a net loss of $89.5 million for the fiscal second quarter ended May 31, 2026, on revenues of $9.0 million, but highlighted a strong pro-forma cash position of approximately $1.14 billion with the Roche payment.
Key Highlights
- Global collaboration with Roche for bexobrutideg, potential total payments up to $2.3 billion.
- Nurix expects to receive a $700 million upfront payment from Roche.
- Development costs for bexobrutideg will be shared 40% by Nurix and 60% by Roche.
- Cash, cash equivalents, and marketable securities were $443.5 million as of May 31, 2026.
- Pro-forma cash is approximately $1.14 billion, including the expected $700 million upfront payment.
- Revenue for Q2 2026 was $9.0 million, down from $44.1 million in Q2 2025.
- Net loss for Q2 2026 was $89.5 million, or ($0.81) per share.
- Bexobrutideg Phase 1a/1b study showed 83% ORR and 22.1 months median PFS in CLL/SLL.
Price Impact
More from NRIX